Three new ferrocenyl oxadiazoles, viz. (E)-2-(4-hydroxyphenyl)-5-(2-ferrocenyl-ethen-1-yl)-1,3,4-oxadiazole (D2), (E)-2-(4-nitrophenyl)-5-(2-ferrocenyl-ethen-1-yl)-1,3,4-oxadiazole (D3) and...
Three new ferrocenyl oxadiazoles, viz. (E)-2-(4-hydroxyphenyl)-5-(2-ferrocenyl-ethen-1-yl)-1,3,4-oxadiazole (D2), (E)-2-(4-nitrophenyl)-5-(2-ferrocenyl-ethen-1-yl)-1,3,4-oxadiazole (D3) and...
To examine the effects of filgotinib, an oral, selective Janus kinase 1 inhibitor, on health-related quality of life (HRQoL) using the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire in active PsA. Methods...
|< |
< |
1 |